Interim Report January-March 2018
“We are targeting marketing authorization approvals in all key markets in 2018” Business highlights first quarter 2018 · Complete response letter (CRL) received by our partner Braeburn Pharmaceuticals from the FDA regarding the CAM2038 new drug application (NDA) for the treatment of opioid use disorder · Type A Meeting Package submitted to the FDA regarding CRL request for additional information for the CAM2038 NDA · CAM2038 marketing approval applications in EU and Australia progressed according to plan · All patients completed treatment in the randomized Phase 3 study of